BPMC News and Press, Blueprint Medicines Corporation From 02/16/22

Blueprint Medicines  press release (NASDAQ:BPMC): Q4 GAAP EPS of -$5.40 misses by $4.25. Revenue of $107M (+213.7% Y/Y) beats by $2.86M. Blueprint Medicines today announced it anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AY...

Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results -- Achieved $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues in 2021 -- -- Anticipate approximately $115 million to $130 million in AYVAKIT net product revenues and $180 m...

Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is -$1.57 and the consensus revenue estimate is $104.14M (+205.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of the time...

Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022 PR Newswire CAMBRIDGE, Mass. , Feb. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a l...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis -- Positive opinion based on results from two clinical trials that comprise the largest clinical trial dataset in advanced systemic mas...

Blueprint Medicines Elevates Two Talented Leaders to its Executive Team -- Philina Lee, Ph.D., promoted to Chief Commercial Officer -- -- Helen Ho, Ph.D., role expanded to Chief Business Officer - -- Demonstrates strong bench of talent and commitment to diversity in role...

Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership -- Achieved full-year 2021 preliminary global net product revenue for AYVAKIT of approximately $52.9 million, representing an increase of approximately 150% over 2020 based on stron...

Blueprint Medicines Announces CEO and Leadership Transition Plan -- Jeff Albers to transition to role of Executive Chairman of the Board of Directors -- -- Chief Operating Officer Kate Haviland appointed President and Chief Executive Officer -- -- Chief Commercial Office...

Blueprint Medicines Completes Acquisition of Lengo Therapeutics - Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations - Investigational New Drug application for LNG-45...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...